FOUR emplois en FRANCE
6 - Permanent - Temps-plein Four emplois en Mayenne sur 1 page(-s)
Chef de Projet Ingénierie H/F
GlaxoSmithKline -
science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas...
GlaxoSmithKline -
Mayenne
- - 26 Jui 2024science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas...
Alternant Affaires Réglementaires Pharmaceutiques Site (H/F)
GlaxoSmithKline -
science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas...
GlaxoSmithKline -
Mayenne
- - 26 Jui 2024science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas...
Responsable Secteur Maintenance H/F - CDI
GlaxoSmithKline -
technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology...
GlaxoSmithKline -
Mayenne
- - 19 Jui 2024technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology...
Technicien(ne) de Maintenance Equipement H/F en CDI
GlaxoSmithKline -
technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology...
GlaxoSmithKline -
Mayenne
- - 18 Jui 2024technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology...
RESPONSABLE D'EQUIPE PRODUCTION
GlaxoSmithKline -
, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology). Our success...
GlaxoSmithKline -
Mayenne
- - 08 Jui 2024, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology). Our success...
Alternant(e) Pharmacien Secteur Industriel H/F
GlaxoSmithKline -
, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology). Our success...
GlaxoSmithKline -
Mayenne
- - 09 Mai 2024, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology). Our success...